SCLX SCLX
Company Profile ↓Company Overview
SCLX (SCLX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $30.25M (-46.5% YoY); net profit $-374.05M.
- Trailing 12 Months Year-on-year growth — revenue -46.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 5.13% |
| 1 Year: | -46.54% |
Stock Price Performance
| 1 Year: | -30.01% |
| 6 Months: | +18.85% |
| 3 Months: | -2.41% |
| 1 Month: | -34.34% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.77 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Trading 65.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 6.81M | 7.93M | 11.38M | 10.58M | 12.58M | 10.12M | 10.88M | 16.37M | 14.44M | 5.00M | 9.90M | 10.56M | 8.61M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.70M | - | - | 25.70M |
| Operating Income | -856 | -165.16K | -172.14K | -283.35K | -8.81M | -11.47M | -10.62M | -25.47M | -22.81M | -38.80M | -19.48M | -15.62M | -19.92M | -27.90M | -20.51M | -186.51M | -32.17M |
| Net Income | -856 | 1.33M | -233.75K | -1.44M | -9.14M | -17.84M | 21.50M | -30.75M | -26.65M | -35.53M | -24.38M | -37.58M | -4.39M | -26.08M | -44.05M | -257.82M | -45.65M |
| Diluted EPS | 0.00 | 0.09 | -0.01 | -0.08 | -0.07 | -0.13 | 0.16 | -0.22 | -0.19 | -0.63 | -8.33 | -7.67 | -0.58 | -2.26 | -7.42 | -22.17 | -6.28 |
| R&D Expense | - | - | - | - | 2.63M | 2.59M | 1.24M | 2.74M | 3.20M | 4.07M | 3.11M | 2.00M | 2.35M | 2.46M | 6.19M | 3.90M | 3.21M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 23.56M | 31.32M | 38.03M | 46.74M | 56.59M | 30.25M |
| Gross Profit | - | - | - | - | 167.40M | 125.80M |
| Operating Income | -35.26M | -35.84M | -50.63M | -105.43M | -83.40M | -346.01M |
| Net Income | -47.52M | -88.42M | -23.36M | -114.33M | -72.81M | -374.05M |
| Diluted EPS | -0.36 | -0.67 | -0.17 | -1.28 | -8.05 | -36.48 |
| R&D Expense | 9.96M | 9.20M | 9.05M | 12.75M | 9.64M | 20.71M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 199.48K | 77.93M | 86.53M | 101.31M | 92.95M | 364.98M |
| Total Equity | -90.03M | 18.72K | -223.88M | 36.24M | -172.94M | -192.64M | -207.78M |
| Cash & Equivalents | - | 30.51K | 4.34M | 2.18M | 3.92M | 3.27M | 4.96M |
| Long Term Debt | - | - | 72.04M | 0 | - | - | - |
| Total Liabilities | - | 180.76K | 301.81M | 50.29M | 274.25M | 285.59M | 576.73M |
| Current Liabilities | - | 180.76K | 169.42M | 44.84M | 250.38M | 259.63M | 483.65M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -31.46M | -28.66M | -21.26M | -20.71M | 19.35M | 3.82M |
| Investing Cash Flow | -25.00K | 0 | -2.07M | -330.00K | -2.67M | 4.08M |
| Financing Cash Flow | -19.17M | 28.16M | 21.17M | 23.58M | -18.13M | -5.46M |
| Capital Expenditure | -25.00K | -0 | -7.00K | -30.00K | -0 | -133.00K |
| Free Cash Flow | -31.49M | -28.66M | -21.27M | -20.74M | 19.35M | 3.68M |
| Dividends Paid | - | - | - | 8.65M | 8.65M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 295.8% | 415.8% |
| Operating Margin % | -149.7% | -114.4% | -133.1% | -225.6% | -147.4% | -1,143.7% |
| Net Margin % | -201.7% | -282.4% | -61.4% | -244.6% | -128.7% | -1,236.4% |
| ROE % | -253,786.6% | 39.5% | -64.5% | 66.1% | 37.8% | 180.0% |
| ROCE % | -188,303.8% | 39.2% | -121.5% | 70.7% | 50.0% | 291.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SCLX
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
PALO ALTO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) (OTC: SMNR) , a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non…
Scilex, Vera Therapeutics rise premarket; Strategy gains
Investing.com - U.S. stock index futures edged higher on Monday as investors returned from a long holiday weekend, with technology shares leading gains.
Scilex Shares Jump After Securing $100 Million Strategic Investment Proposal (SCLX)
Binding Term Sheet Supports Growth PlansScilex Holding Company (NASDAQ:SCLX) shares climbed 7% on Monday after the company announced it had signed a binding term sheet for a proposed $100 million strategic investment from Kazakhstan-based p…
Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain managemen…
ZTlido Emerges as Top Non-Opioid Pain Therapy: Market Expansion and Physician Adoption Insights
ZTlido's market opportunities include strong sales momentum, expanding prescription share, favorable positioning as a non-opioid amid the opioid crisis, improved formulation, and increased payer access. These factors, alongside robust IP pr…
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highl…
SCLX — Frequently Asked Questions
What is the current share price of SCLX?
As of 2026-08-05 17:25 PDT, SCLX trades at $6.52 on NASDAQ/NYSE. Its 52-week range is $3.69 to $18.68.
What is the P/E ratio of SCLX?
SCLX trades at a trailing price-to-earnings (P/E) ratio of -0.18.
Is SCLX a good stock to buy?
This page provides a data-driven analysis of SCLX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.